Literature DB >> 3395377

Altered responsiveness of adenylate cyclase to adenosine and other agents in the myocardial sarcolemma and aorta of spontaneously-hypertensive rats.

M B Anand-Srivastava1.   

Abstract

Adenylate cyclase activity was studied in the myocardial sarcolemma and aorta of spontaneously-hypertensive rats (SHR) and their respectively Wistar-Kyoto (WKY) controls. Basal enzyme activity was decreased in the SHR as compared to the WKY group. Adenylate cyclase stimulation by N-ethylcarboxamide adenosine (NECA) was significantly lower in the myocardial sarcolemma and aorta of SHR, and this decreased responsiveness was associated with a reduction in the Vmax. Other agonists, such as isoproterenol (ISO), epinephrine, dopamine (DA), and glucagon, also enhanced myocardial adenylate cyclase activity to various degrees in SHR and WKY, but stimulation (Vagonists/Vbasal) was always lower in the SHR. NaF and forskolin (FSK), which activate adenylate cyclase via receptor-independent mechanisms, augmented it in the myocardial sarcolemma of SHR to a lesser extent than in WKY. While the guanine nucleotides GTP and GMP-P(NH)P elevated adenylate cyclase in a concentration-dependent manner in both SHR and WKY, the magnitude of stimulation was significantly lower in the former group. Decreased basal adenylate cyclase activity and responsiveness to adenosine, various hormones, NaF and FSK were observed in SHR of all ages, i.e. from 4 to 24 weeks of age. In addition, basal, hormone-, NaF- and FSK-stimulated adenylate cyclase activity was diminished markedly in the aorta of SHR. These results suggest that, in SHR, not only is basal adenylate cyclase activity decreased but the abilities of adenosine, other hormones and agonists, such as NaF and FSK, to stimulate adenylate cyclase, guanine nucleotide regulatory protein and the catalytic subunit of the cyclase system are also impaired in the myocardial sarcolemma and aorta.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3395377     DOI: 10.1016/0006-2952(88)90291-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

2.  Differential regulation of G-protein expression by vasoactive peptides.

Authors:  M B Anand-Srivastava; A Palaparti; J Pion
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

Review 3.  Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.

Authors:  Michel Félétou; Yu Huang; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Characterization of adenylyl cyclase in heart sarcolemma in the absence or presence of alamethicin.

Authors:  R Sethi; K S Dhalla; K R Shah; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

5.  Transgenic rescue of defective Cd36 enhances myocardial adenylyl cyclase signaling in spontaneously hypertensive rats.

Authors:  Martina Klevstig; Dmitry Manakov; Dita Kasparova; Iveta Brabcova; Frantisek Papousek; Jitka Zurmanova; Vaclav Zidek; Jan Silhavy; Jan Neckar; Michal Pravenec; Frantisek Kolar; Olga Novakova; Jiri Novotny
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

6.  Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition.

Authors:  M B Anand-Srivastava
Journal:  Biochem J       Date:  1992-11-15       Impact factor: 3.857

7.  G-proteins and adenylyl cyclase signalling in hypertension.

Authors:  M B Anand-Srivastava
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

8.  Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and Oxidative Stress.

Authors:  Madhu B Anand-Srivastava
Journal:  Curr Cardiol Rev       Date:  2010-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.